Vaccine boost tempts Caixa, ING into senior market

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Vaccine boost tempts Caixa, ING into senior market

Vaccine_news_PA_575x375_101120
Topic picture, symbol photo: Corona vaccine. Pfizer and BioNTech Announce Successful First Interim Analysis of their COVID-19 Vaccine Candidate in Current Phase 3 Trial A hand wrapped in rubber gloves holds a disposable syringe of vaccine for injection in a needle BIONTECH biotechnology company. | usage worldwide | FrankHoemann/SVEN SIMON/DPA/PA Images

Deal arrangers expect banks will take advantage of a positive tone in the euro market by bringing forward their plans for non-preferred senior issuance, following in the footsteps of CaixaBank and ING Groep on Tuesday.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article